2020
DOI: 10.1016/j.alit.2019.08.002
|View full text |Cite
|
Sign up to set email alerts
|

Eosinophilic cholangitis with eosinophilic granulomatosis with polyangiitis: A case report and review of the literature

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

0
4
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(4 citation statements)
references
References 8 publications
0
4
0
Order By: Relevance
“…The prognosis and frequency of eosinophilic cholangiopathy with EGPA remain elusive. Previously, only 19 cases of EGPA in conjunction with eosinophilic cholecystitis have been reported [ 6 – 23 ], while only 2 studies reported EGPA together with eosinophilic cholangitis [ 24 , 25 ]. Most of the reported cases had a histopathological diagnosis, but in the present case, the contemporaneous appearance of EGPA and cholecystitis was diagnosed based on the patient’s symptoms, laboratory test results, and imaging findings, without a pathological diagnosis.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The prognosis and frequency of eosinophilic cholangiopathy with EGPA remain elusive. Previously, only 19 cases of EGPA in conjunction with eosinophilic cholecystitis have been reported [ 6 – 23 ], while only 2 studies reported EGPA together with eosinophilic cholangitis [ 24 , 25 ]. Most of the reported cases had a histopathological diagnosis, but in the present case, the contemporaneous appearance of EGPA and cholecystitis was diagnosed based on the patient’s symptoms, laboratory test results, and imaging findings, without a pathological diagnosis.…”
Section: Discussionmentioning
confidence: 99%
“…In general, EGPA is mainly treated with PDN; the EGPA practice guidelines recommend the use of PDN or cyclophosphamide for remission induction therapy and AZA for remission maintenance therapy [ 32 ]. In a recent case report, eosinophilic cholangitis, in conjunction with EGPA, was successfully treated by combining PDN and mepolizumab [ 24 ]. In the present case, PDN was administered in monotherapy, without the addition of cyclophosphamide or mepolizumab, which was sufficient to induce remission, while AZA was added to maintain it.…”
Section: Discussionmentioning
confidence: 99%
“…Generally, an allergic response to any antigen is assumed to be the cause. Nevertheless, the causative agent in each case has not always been identified (5)(6)(7)(8)(9)(10)(11).…”
Section: Discussionmentioning
confidence: 99%
“…12 Involvement of the hepatobiliary system in EGPA is very rare but has been reported. 13 The pathogenesis of EGPA remains largely unknown, but abnormal eosinophilic proliferation and tissue toxicity from eosinophil-derived proteins are thought to play major roles. 7 Eosinophils are complex cells that produce an array of molecules with diverse functions.…”
Section: Discussionmentioning
confidence: 99%